2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Promyelocytic, Acute
2
Leukemia, Myeloid, Acute
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
25
Cisplatin
18
Carboplatin
10
Paclitaxel
9
Specimen Handling
6
Nivolumab
6
Doxorubicin
6
Docetaxel
6
pembrolizumab
5
Magnetic Resonance Spectroscopy
5
cabozantinib
4
avelumab
4
Vinblastine
4
Radiotherapy
4
Methotrexate
4
Fluorouracil
4
enfortumab vedotin
3
atezolizumab
3
aflibercept
3
Trastuzumab
3
Sunitinib
3
Ramucirumab
3
Platinum
3
Ipilimumab
3
Immunoglobulin G
3
Disulfides
3
CTLA-4 Antigen
3
Biopsy
3
1,2-diaminocyclohexaneplatinum II citrate
3
vinflunine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urethral Neoplasms
×
tamibarotene
×
Clear all
NCT06983210
2025-08-14
GRAPE
Nagoya University
Phase 2
Recruiting
43 enrolled